These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 11889149

  • 1. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [Abstract] [Full Text] [Related]

  • 2. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.
    Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
    [Abstract] [Full Text] [Related]

  • 3. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
    Hagino H, Tanaka S, Kuroda T, Mori S, Soen S.
    J Bone Miner Metab; 2024 May; 42(3):382-388. PubMed ID: 38755328
    [Abstract] [Full Text] [Related]

  • 4. Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.
    Natsag J, Kendall MA, Sellmeyer DE, McComsey GA, Brown TT.
    HIV Med; 2016 Mar; 17(3):196-205. PubMed ID: 26177791
    [Abstract] [Full Text] [Related]

  • 5. Alendronate and raloxifene therapy in the early period after hip fracture.
    Ohishi T, Ichikawa T, Ito T, Koyama H, Miyagi M, Hoshino H, Takahashi M.
    J Rural Med; 2011 Mar; 6(1):16-21. PubMed ID: 25650026
    [Abstract] [Full Text] [Related]

  • 6. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ.
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N, Bone H, Gilligan JP, Krause DS.
    Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
    [Abstract] [Full Text] [Related]

  • 8. Raloxifene for older women: a review of the literature.
    Hansdóttir H.
    Clin Interv Aging; 2008 Nov; 3(1):45-50. PubMed ID: 18488877
    [Abstract] [Full Text] [Related]

  • 9. Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level.
    Chavassieux P, Roux JP, Chapurlat R.
    Osteoporos Int; 2024 Apr; 35(4):653-658. PubMed ID: 38129674
    [Abstract] [Full Text] [Related]

  • 10. Twelve-month consumption of a polyphenol extract from olive (Olea europaea) in a double blind, randomized trial increases serum total osteocalcin levels and improves serum lipid profiles in postmenopausal women with osteopenia.
    Filip R, Possemiers S, Heyerick A, Pinheiro I, Raszewski G, Davicco MJ, Coxam V.
    J Nutr Health Aging; 2015 Jan; 19(1):77-86. PubMed ID: 25560820
    [Abstract] [Full Text] [Related]

  • 11. Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China.
    Zhang Y, Wang Y.
    J Nutr Health Aging; 2020 Jan; 24(5):485-493. PubMed ID: 32346686
    [Abstract] [Full Text] [Related]

  • 12. Prevention and treatment of postmenopausal osteoporosis.
    Tella SH, Gallagher JC.
    J Steroid Biochem Mol Biol; 2014 Jul; 142():155-70. PubMed ID: 24176761
    [Abstract] [Full Text] [Related]

  • 13. Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.
    Ther Clin Risk Manag; 2010 Apr 26; 6():201-6. PubMed ID: 20463781
    [Abstract] [Full Text] [Related]

  • 14. Correlation between bone mineral density and bone metabolic markers in postmenopausal women with osteoporotic fractures at different C-terminal telopeptide of type 1 collagen levels: a retrospective analysis study.
    Zhu X, Chen L, Pan L, Zeng Y, Fu Q, Liu Y, Peng Y, Wang Y, You L.
    Menopause; 2023 Nov 01; 30(11):1139-1146. PubMed ID: 37847873
    [Abstract] [Full Text] [Related]

  • 15. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans.
    Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM.
    J Bone Miner Res; 2008 Dec 01; 23(12):1974-82. PubMed ID: 18684084
    [Abstract] [Full Text] [Related]

  • 16. One versus 2 years of alendronate following denosumab: the CARD extension.
    Tsai JN, Jordan M, Lee H, Leder BZ.
    Osteoporos Int; 2024 Aug 07. PubMed ID: 39112628
    [Abstract] [Full Text] [Related]

  • 17. Bone quality in zebrafish vertebrae improves after alendronate administration in a glucocorticoid-induced osteoporosis model.
    Bohns FR, Akhtar R, Chuang YJ, Chen PY.
    J Mech Behav Biomed Mater; 2024 Jun 07; 154():106521. PubMed ID: 38555661
    [Abstract] [Full Text] [Related]

  • 18. Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures.
    Iwamoto J, Miyata A, Sato Y, Takeda T, Matsumoto H.
    Ther Clin Risk Manag; 2009 Jun 07; 5():773-9. PubMed ID: 19851524
    [Abstract] [Full Text] [Related]

  • 19. Plasma periostin as a biomarker of osteoporosis in postmenopausal women with type 2 diabetes.
    Li J, Niu X, Si Q, Song Q, Jin M, Zhou R, Sun Y, Li J, Wang Q.
    J Bone Miner Metab; 2021 Jul 07; 39(4):631-638. PubMed ID: 33566208
    [Abstract] [Full Text] [Related]

  • 20. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss.
    Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR.
    J Clin Endocrinol Metab; 2009 Sep 07; 94(9):3356-64. PubMed ID: 19549739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.